HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.